Portrait of Wes Streeting
Politician · policy
Wikipedia (opens in new tab)

Wes Streeting on Puberty Blockers

Indefinite restriction (strong)

TL;DR

Wes Streeting indefinitely restricted puberty blockers for under-18s based on expert clinical advice due to safety concerns.

Key Points

  • He delivered a statement to Parliament in December 2024 confirming an indefinite restriction on the private and UK-prescribed supply of puberty blockers to under-18s.

  • The decision was explicitly based on the recommendation from the independent Commission on Human Medicines to extend previous temporary bans due to unacceptable safety risks.

  • He confirmed support for a new NHS clinical trial, recommended by the Cass Review, to build a robust evidence base for the use of puberty-suppressing hormones.

Summary

The Health and Social Care Secretary, Wes Streeting, announced an indefinite order restricting the sale or supply of puberty blockers to individuals under 18 in the UK in December 2024. This decision was directly based on the advice of the independent Commission on Human Medicines, which concluded that prescribing these drugs for gender dysphoria presented an "unacceptable safety risk" in the current prescribing environment. This followed the cessation of routine use by NHS England, based on the Cass Review's finding of "remarkably weak" evidence regarding the long-term effects and effectiveness of these drugs for gender incongruence in children.

Despite admitting personal discomfort with medication that halts a natural human development, he stated his commitment to evidence-led healthcare, which necessitated following the expert clinical recommendations. He simultaneously emphasized the government’s commitment to improving healthcare for trans people and supported a new, world-first clinical trial to establish a robust evidence base for puberty-suppressing hormones. The ongoing restrictions were set to be reviewed in 2027, pending an updated assessment of the prescribing environment and the results of the new research.

Key Quotes

“It has not sat easily with me at all,” Streeting said, “that there are young people who describe to me how they feel about not being able to access puberty blockers.”

Frequently Asked Questions

Wes Streeting's position is to indefinitely restrict the prescription of puberty blockers to minors based on expert clinical advice regarding safety and evidence. He defended this ban as necessary to protect vulnerable young people from irreversible harm, according to a statement in December 2024.

As Secretary of State, Wes Streeting continued and made permanent restrictions that his party supported when in opposition, maintaining a cautious approach. He admitted to being 'deeply uncomfortable' with the medication but confirmed he planned to follow the clinical advice to proceed with the evidence-gathering trial.

Wes Streeting stated that the government is committed to the clinical trial for puberty blockers, calling it the first of its kind globally. He argued that only this trial can isolate the effects of the treatments, supporting evidence-based decisions for future care, as he defended in a statement to Parliament.